U.S. Genetic Testing Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: U.S. Genetic Testing Market
- ✓Market Size 2024: USD 18.4 billion
- ✓Market Size 2032: USD 34.9 billion
- ✓CAGR: 8.3%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Secure MolDX Submissions Early: Investors and laboratory buyers should prioritize MolDX technical assessment submissions for hereditary cancer and pharmacogenomic panels before Q2 2026, since Medicare coverage decisions set reimbursement for most U.S. genetic tests. Delay risks losing payer access.
Genetic Testing in the United States: Market Overview
The U.S. genetic testing market was valued at USD 18.4 billion in 2024 and is forecast to reach USD 34.9 billion by 2032, growing at 8.3% annually. Laboratory volume is concentrated in national reference laboratories such as Quest Diagnostics and Labcorp, which operate broad clinical laboratory networks, alongside specialist genomics firms. Clinical testing dominates revenue, with germline and somatic oncology panels accounting for the largest share.
Government has shaped the market's form mainly through payment rules rather than direct ownership. CMS sets Medicare coverage and reimbursement through the Clinical Laboratory Fee Schedule and MolDX, administered by Palmetto GBA, while the Department of Health and Human Services funds newborn screening through HRSA. Private innovation, led by Natera's non-invasive prenatal testing and Myriad Genetics' hereditary cancer panels, has driven commercial growth where public coverage followed clinical evidence.
Policy-Driven Growth in US Genetic Testing
The 21st Century Cures Act of 2016 authorized USD 4 billion for the NIH Precision Medicine Initiative over ten years, funding the All of Us Research Program's genomic data collection. That cohort supplies the variant-interpretation data that private laboratories such as GeneDx and Myriad Genetics draw on to validate panels. Mechanism: public research funding lowers validation cost for private laboratories, shortening the path from research sequencing to commercial test.
CMS National Coverage Determination 90.2, effective 2018, covers next-generation sequencing for Medicare beneficiaries with advanced cancer when tests are FDA-approved or performed in CLIA-certified laboratories. Coverage removes the out-of-pocket barrier that previously restricted tumor profiling, so volumes at Guardant Health and Foundation Medicine scale directly with this mandate. HRSA's newborn screening program, authorized under the Newborn Screening Saves Lives Reauthorization Act of 2014, separately funds state screening programs that increasingly adopt genomic sequencing.
Regulatory Barriers and Compliance Costs
Clinical laboratories must hold a CLIA certificate issued through the Centers for Medicare and Medicaid Services before reporting patient results, with annual certificate fees and proficiency testing requirements scaling by test complexity. New York adds a further gate: the New York State Department of Health Clinical Laboratory Evaluation Program must approve each test offered to New York residents, a review that extends launch timelines by months.
Genetic data carries separate liability under the Genetic Information Nondiscrimination Act of 2008, whose employment provisions the Equal Employment Opportunity Commission enforces, and under state statutes that exceed federal floors. Illinois' Genetic Information Privacy Act allows statutory damages of USD 2,500 per negligent violation and USD 15,000 per reckless violation, while California's Genetic Information Privacy Act (SB 41, effective 2022) requires separate written consent for each genetic test and onward disclosure. Multistate consent workflows add substantial compliance cost for direct-to-consumer providers.
Policy-Created Opportunities in the United States
FDA's Table of Pharmacogenomic Biomarkers in Drug Labeling lists drug-gene pairs with actionable prescribing information, creating a regulatory pull for pharmacogenomic testing. Laboratories that validate panels against listed biomarkers, including CYP2C19 and CYP2D6, can address clinician demand that the table has formalized across oncology, psychiatry and cardiology. Commercial volumes follow where electronic health record alerts link results directly to prescribing decisions.
The Million Veteran Program, administered by the U.S. Department of Veterans Affairs, has enrolled more than one million veterans for genomic research, creating a federal demand channel for sequencing services and data platforms. Separately, the Department of Justice's Bulk Sensitive Data Rule under Executive Order 14117, effective April 8, 2025, restricts transfers of human genomic data to countries of concern, favoring U.S.-based sequencing and data processing providers.
Market at a Glance
| Metric | Value |
|---|---|
| Market Size 2024 | USD 18.4 billion |
| Market Size 2032 | USD 34.9 billion |
| Growth Rate (CAGR) | 8.3% |
| Most Critical Decision Factor | Medicare coverage and reimbursement determination |
| Largest Region | South (U.S. Census Region) |
| Competitive Structure | Consolidated leaders with fragmented specialist challengers |
Leading Market Participants
- Quest Diagnostics
- Labcorp
- Natera
- Exact Sciences
- Myriad Genetics
- GeneDx
- Guardant Health
- Illumina
- Tempus AI
- Veracyte
Frequently Asked Questions
Market Segmentation
- Regulatory and Policy Environment
- The Clinical Laboratory Improvement Amendments of 1988 remain the primary legislative framework, administered by CMS, with FDA responsible for device classification. FDA's final rule extending device regulation to laboratory-developed tests was vacated by the U.S. District Court for the Eastern District of Texas in American Clinical Laboratory Association v. FDA on March 31, 2025, returning these tests to CLIA oversight. Compliance today requires CLIA certification, Medicare coverage through MolDX, state licensure in New York, and DOJ bulk data obligations.
- Upcoming changes include the DOJ Bulk Sensitive Data Rule's due diligence, audit and reporting obligations, which take effect on October 6, 2025, and continuing PAMA reporting cycles that reset Medicare Clinical Laboratory Fee Schedule rates. Compared with regional peers, the EU's In Vitro Diagnostic Regulation (EU) 2017/746 requires notified-body certification for most tests, with transition periods extending to 2027–2029, while the U.S. framework permits laboratories to offer laboratory-developed tests without premarket review.
- Long-Term Policy Outlook for Genetic Testing in the United States
- Congress has not enacted the VALID Act or any successor laboratory-developed test legislation, so CLIA and Medicare coverage will govern genetic testing through 2032. Pending Medicare multi-cancer early detection screening legislation would create the first national coverage pathway for blood-based multi-cancer tests, reshaping volumes for Grail and Guardant Health.
- PAMA reporting cycles will continue to reset rates for high-volume genetic tests, pressuring margins at commodity panel providers such as Quest Diagnostics and Labcorp while rewarding MolDX-validated specialists. The DOJ rule's data-localization requirements will drive onshoring of sequencing and bioinformatics capacity in the U.S. by 2032, with Illumina and domestic laboratories capturing federal procurement.
- Market Segmentation
- Hereditary Cancer Testing
- Pharmacogenomic Testing
- Prenatal and Newborn Screening
- Oncology Somatic Profiling
- Reference Laboratories
- Hospitals and Health Systems
- Direct-to-Consumer Platforms
- Academic Research Centers
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.